CR20140586A - Celulas para producir iduronato-2-sulfatasa recombinante - Google Patents

Celulas para producir iduronato-2-sulfatasa recombinante

Info

Publication number
CR20140586A
CR20140586A CR20140586A CR20140586A CR20140586A CR 20140586 A CR20140586 A CR 20140586A CR 20140586 A CR20140586 A CR 20140586A CR 20140586 A CR20140586 A CR 20140586A CR 20140586 A CR20140586 A CR 20140586A
Authority
CR
Costa Rica
Prior art keywords
cells
iduronate
produce
recombinant
sulfatase
Prior art date
Application number
CR20140586A
Other languages
English (en)
Spanish (es)
Inventor
Ferenc Boldog
Michael Heartlein
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of CR20140586A publication Critical patent/CR20140586A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0051Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y108/00Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CR20140586A 2012-06-29 2014-12-17 Celulas para producir iduronato-2-sulfatasa recombinante CR20140586A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666719P 2012-06-29 2012-06-29
PCT/US2013/048571 WO2014005019A2 (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
CR20140586A true CR20140586A (es) 2015-04-06

Family

ID=49778522

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140586A CR20140586A (es) 2012-06-29 2014-12-17 Celulas para producir iduronato-2-sulfatasa recombinante

Country Status (27)

Country Link
US (3) US9150841B2 (enExample)
EP (1) EP2874649B1 (enExample)
JP (3) JP6067849B2 (enExample)
KR (1) KR101710487B1 (enExample)
CN (2) CN104540517A (enExample)
AU (3) AU2013282400B2 (enExample)
BR (1) BR112014032560B1 (enExample)
CA (1) CA2877521C (enExample)
CL (1) CL2014003568A1 (enExample)
CO (1) CO7240394A2 (enExample)
CR (1) CR20140586A (enExample)
DO (1) DOP2014000298A (enExample)
EA (2) EA035511B1 (enExample)
ES (1) ES2718346T3 (enExample)
GT (1) GT201400302A (enExample)
HK (1) HK1209331A1 (enExample)
IL (3) IL236343A (enExample)
MX (2) MX336716B (enExample)
MY (2) MY189314A (enExample)
NZ (2) NZ703137A (enExample)
PE (1) PE20150957A1 (enExample)
PH (2) PH12016500011B1 (enExample)
SG (2) SG11201408702VA (enExample)
TR (1) TR201904435T4 (enExample)
UA (1) UA118955C2 (enExample)
WO (1) WO2014005019A2 (enExample)
ZA (1) ZA201409396B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドModernaTX,Inc. 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2844737B1 (en) * 2012-05-02 2018-03-21 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
US9550972B2 (en) 2014-09-29 2017-01-24 General Electric Company Devices, systems and methods for automated cell culturing
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
JP2021500857A (ja) 2017-10-02 2021-01-14 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 酵素補充療法用酵素を含む融合タンパク質
JP7060235B2 (ja) * 2018-05-18 2022-04-26 国立大学法人広島大学 変異型イズロン酸-2-スルファターゼの機能回復薬剤のスクリーニング方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
EP0750511B1 (en) 1994-03-16 2003-06-11 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
IL145893A0 (en) 1999-04-26 2002-07-25 Genentech Inc Cell culture process for glycoproteins
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
CA2383800A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences Inc. 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
CA2400034A1 (en) 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
JP2003527851A (ja) 2000-03-17 2003-09-24 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 7つのヒト卵巣および卵巣癌関連タンパク質
WO2001079444A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
KR100788093B1 (ko) 2002-04-26 2007-12-21 제넨테크, 인크. 단백질의 비친화성 정제
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
PL377731A1 (pl) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
CN101444621B (zh) 2003-02-11 2013-11-20 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
ES2370417T3 (es) 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
SI3219795T1 (sl) 2008-01-18 2024-10-30 Biomarin Pharmaceutical Inc. Izdelava akitvnih visoko fosforiliranih humanih encimov lizomske sulfataze in njihova uporaba
PL2485761T3 (pl) 2009-10-09 2019-10-31 Armagen Inc Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns
CN105664811B (zh) * 2009-10-09 2018-10-09 蓝立方知识产权公司 生产氯化和/或氟化丙烯和高级烯烃的绝热活塞流反应器及方法
JPWO2011108451A1 (ja) 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
ES2754234T3 (es) 2010-06-25 2020-04-16 Shire Human Genetic Therapies Métodos y composiciones para la administración SNC de iduronato-2-sulfatasa
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제

Also Published As

Publication number Publication date
KR20150030242A (ko) 2015-03-19
PH12014502868A1 (en) 2015-02-23
IL254560A0 (en) 2017-11-30
AU2016200460A1 (en) 2016-02-18
IL274266B (en) 2021-04-29
PE20150957A1 (es) 2015-07-15
AU2016200460B2 (en) 2017-11-02
PH12016500011A1 (en) 2019-08-14
BR112014032560A2 (pt) 2018-03-06
UA118955C2 (uk) 2019-04-10
CN107267460A (zh) 2017-10-20
MY157086A (en) 2016-04-19
SG11201408702VA (en) 2015-02-27
MY189314A (en) 2022-02-04
US9719074B2 (en) 2017-08-01
AU2013282400A1 (en) 2015-01-29
US20160053238A1 (en) 2016-02-25
EP2874649A4 (en) 2016-05-04
BR112014032560B1 (pt) 2022-04-26
ES2718346T3 (es) 2019-07-01
ZA201409396B (en) 2018-05-30
EA202090805A1 (ru) 2020-11-30
JP6067849B2 (ja) 2017-01-25
IL274266A (en) 2020-06-30
MX336716B (es) 2016-01-28
SG10201509397SA (en) 2015-12-30
NZ734670A (en) 2019-12-20
HK1209331A1 (en) 2016-04-01
EP2874649A2 (en) 2015-05-27
PH12014502868B1 (en) 2015-02-23
IL236343A (en) 2017-10-31
JP2016105737A (ja) 2016-06-16
CA2877521C (en) 2021-06-01
CL2014003568A1 (es) 2015-04-24
HK1209651A1 (en) 2016-04-08
AU2013282400B2 (en) 2016-02-04
GT201400302A (es) 2019-05-22
WO2014005019A3 (en) 2014-02-27
MX2015000189A (es) 2015-04-08
MX366155B (es) 2019-06-28
US20180010108A1 (en) 2018-01-11
TR201904435T4 (tr) 2019-05-21
DOP2014000298A (es) 2015-03-31
CA2877521A1 (en) 2014-01-03
JP2018088933A (ja) 2018-06-14
AU2018200710A1 (en) 2018-02-22
JP6302499B2 (ja) 2018-03-28
JP6755272B2 (ja) 2020-09-16
PH12016500011B1 (en) 2022-07-15
EA035511B1 (ru) 2020-06-26
CN104540517A (zh) 2015-04-22
IL254560B (en) 2020-05-31
CO7240394A2 (es) 2015-04-17
NZ703137A (en) 2017-08-25
US20140004593A1 (en) 2014-01-02
WO2014005019A2 (en) 2014-01-03
EA201492183A1 (ru) 2015-06-30
AU2018200710B2 (en) 2019-11-14
US9150841B2 (en) 2015-10-06
KR101710487B1 (ko) 2017-02-27
JP2015521848A (ja) 2015-08-03
IL236343A0 (en) 2015-02-26
EP2874649B1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
CR20140586A (es) Celulas para producir iduronato-2-sulfatasa recombinante
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
UY34333A (es) ?métodos y composiciones para el control de malezas, y métodos para reducir la expresión de enzima dhps?
UY34822A (es) Composiciones y métodos para silenciar la expresión genética
EP4520817A3 (en) In vitro production of medial ganglionic eminence precursor cells
TWD165137S (zh)
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
IL240644B (en) Cell culture compositions with antioxidants and methods for polypeptide production
UY34751A (es) ?composición de pienso para reducir la metanogénesis en rumiantes?
MX2015001553A (es) Composiciones y metodos para reducir el contenido de alcohol en sangre.
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
EP2970885A4 (en) Expansion of adult stem cells in vitro
CR20140588A (es) Purificación de iduronato-2-sulfatasa
EP2961829A4 (en) GENERATION OF THYME PEPPER THERAPEUTIC CELLS IN VITRO
CR20140587A (es) Metodo para producir iduronato-2-sulfatasa recombinante
IN2014DN03298A (enExample)
WO2014182684A3 (en) Methods and compositions related to large scale production of proteins
BR112014021326A2 (pt) célula para a expressão de protéina, método para reduzir a atividade de amidação de peptídeo em uma determinada célula, uso de uma célula
EA201492280A1 (ru) Стабильный состав пексиганана
AR091904A1 (es) Un metodo para preparar tirosinasa humana recombinante
AR094875A1 (es) Formulaciones y procedimientos para la producción de proteína recombinante aumentada
TWD169459S (zh) 端子台
TN2013000056A1 (en) Modified relaxin polypeptides and their uses
EA201792475A1 (ru) Клетки-предшественники мезодермальной линии